These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27504556)

  • 21. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association.
    Hernández Madrid A; Potpara TS; Dagres N; Chen J; Larsen TB; Estner H; Todd D; Bongiorni MG; Sciaraffia E; Proclemer A; Cheggour S; Amara W; Blomstrom-Lundqvist C
    Europace; 2016 Mar; 18(3):463-7. PubMed ID: 26899998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel oral anticoagulants to prevent stroke in atrial fibrillation.
    Verheugt FW
    Nat Rev Cardiol; 2010 Mar; 7(3):149-54. PubMed ID: 20179722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
    Halperin JL; Dorian P
    Curr Cardiol Rev; 2014 Nov; 10(4):297-302. PubMed ID: 24821657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey.
    Lip GY; Bongiorni MG; Dobreanu D; Lewalter T; Hastrup Svendsen J; Blomström-Lundqvist C;
    Europace; 2013 Oct; 15(10):1526-32. PubMed ID: 24072770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
    Weitz JI; Eikelboom J
    Thromb Haemost; 2016 Jan; 115(2):257-70. PubMed ID: 26466666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.
    Potpara TS; Ferro CJ; Lip GYH
    Nat Rev Nephrol; 2018 May; 14(5):337-351. PubMed ID: 29578207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New oral anticoagulants in non-valvular atrial fibrillation.
    Francia P; Adduci C; Santini D; Musumeci B; Tocci G
    High Blood Press Cardiovasc Prev; 2013 Jun; 20(2):53-60. PubMed ID: 23653173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Stroke Associated with Atrial Fibrillation and Novel Oral Anticoagulants (NOACs)].
    Ieko M
    Rinsho Byori; 2014 Oct; 62(10):948-57. PubMed ID: 27526540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Xiang CL; Gong YZ; Zeng LJ; Wang R; Kea S; Chaudhary N; Tu RH; He Y
    Acta Cardiol; 2016 Jun; 71(3):349-57. PubMed ID: 27594130
    [No Abstract]   [Full Text] [Related]  

  • 33. New oral anticoagulants in atrial fibrillation.
    Turpie AG
    Eur Heart J; 2008 Jan; 29(2):155-65. PubMed ID: 18096568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation.
    Mtwesi V; Amit G
    Med Clin North Am; 2019 Sep; 103(5):847-862. PubMed ID: 31378330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anticoagulation for patients with non-valvular atrial fibrillation].
    Mizoguchi T; Yasaka M
    Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation.
    Lu Y; Branstad R; Karim RM; Asinger RW
    J Clin Pharm Ther; 2014 Dec; 39(6):628-36. PubMed ID: 25252149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visual Aid Tool to Improve Decision Making in Anticoagulation for Stroke Prevention.
    Saposnik G; Joundi RA
    J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2380-5. PubMed ID: 27318647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Warfarin in non-valvular atrial fibrillation.
    Dalby AJ; Wessels P; Opie LH
    S Afr Med J; 2013 Oct; 103(12):901-4. PubMed ID: 24300625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anticoagulation with atrial fibrillation].
    Zellerhoff S; Goette A; Kirchhof P
    Herzschrittmacherther Elektrophysiol; 2006 Jun; 17(2):89-94. PubMed ID: 16786467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.